Shots:

• The approval is based on P-III study which involved assessing of kynmobi vs PBO in patients with Parkinson’s Disease Off Episodes
• The study resulted in improvements in motor symptoms at 30 minutes after dosing @12 wks.- mean reduction of 7.6 points- initial clinical improvements were seen at 15 minutes post-administration full ON response within 30 minutes @12wks.- well-tolerated
• Kynmobi sublingual film used to treat short-term (acute)- intermittent “off” episodes in people with Parkinson’s disease with expected availability in Sep 2020

Click here to read full press release/ article | Ref: Sunovion Pharmaceuticals | Image: Twitter